Search results
Showing 3301 to 3350 of 4090 results for patient
Cardiovascular disease prevention: risk assessment (modifiable risk factors) (IND270)
This indicator covers the percentage of people aged 43 to 84 years with a modifiable risk factor who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
In development Reference number: GID-TA11351 Expected publication date: TBC
Evidence-based recommendations on balloon angioplasty with or without stenting for coarctation or recoarctation of the aorta in adults and children. This involves gently inflating a balloon in the narrow area of the aorta to widen it so blood can flow more easily.
View recommendations for HTG45Show all sections
Sections for HTG45
This guideline covers preventing, assessing and managing mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It aims to improve assessment and support for mental health conditions, and help people with learning disabilities and their families and carers to be involved in their care.
This guideline covers the care of women with a singleton pregnancy at increased risk of, or with symptoms and signs of, preterm labour (before 37 weeks), and women with a singleton pregnancy having a planned preterm birth. It aims to reduce the risks of preterm birth for the baby and describes treatments to prevent or delay early labour and birth.
Chronic heart failure in adults: diagnosis and management (NG106)
This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.
Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making
Discontinued Reference number: GID-TA10133
In development Reference number: GID-TA11356 Expected publication date: TBC
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]
In development Reference number: GID-HST10062 Expected publication date: TBC
Our stakeholders are involved in the development of NICE guidance and quality standards to ensure that the recommendations are relevant, practical, and meet the needs of those affected by the health or social care issues addressed.
Membership details, terms of reference, future meeting dates and past meeting minutes for our indicator advisory committee.
Our stakeholders are involved in the development of NICE guidance and quality standards to ensure that the recommendations are relevant, practical, and meet the needs of those affected by the health or social care issues addressed.
Membership details, terms of reference, future meeting dates and past meeting minutes for our indicator advisory committee.
Find out what guidance is being considered for development
This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.
Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.
Volanesorsen for treating familial chylomicronaemia syndrome (HST13)
Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults.
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)
Discontinued Reference number: GID-DT14
Learning disability: care and support of people growing older (QS187)
This quality standard covers identifying, assessing and regularly reviewing the care and support needs of people with a learning disability as they grow older. People with a learning disability have many of the same age-related health and social care needs as other people, but this quality standard focuses on the specific challenges associated with their learning disability. It describes high-quality care in priority areas for improvement.
View quality statements for QS187Show all sections
Discontinued Reference number: GID-TAG526
Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)
This guideline covers diagnosing and managing chronic obstructive pulmonary disease or COPD (which includes emphysema and chronic bronchitis) in people aged 16 and older. It aims to help people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce symptoms, improve quality of life and keep them healthy for longer.
Physical activity: brief advice for adults in primary care (PH44)
This guideline covers providing brief advice on physical activity to adults in primary care. It aims to improve health and wellbeing by raising awareness of the importance of physical activity and encouraging people to increase or maintain their activity level.
We want you to be involved in our work - whether you’re commenting on our draft recommendations, taking part in guidance development or attending a committee meeting, your voice is important to us.
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]
Discontinued Reference number: GID-TA10065
This guideline covers identifying, assessing and managing alcohol-use disorders (harmful drinking and alcohol dependence) in adults and young people aged 10 to 17 years. It aims to reduce harms (such as liver disease, heart problems, depression and anxiety) from alcohol by improving assessment and setting goals for reducing alcohol consumption.
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development Reference number: GID-TA10555 Expected publication date: TBC
In development Reference number: GID-TA11277 Expected publication date: TBC
NICE public committee meetings supports our commitment to having processes in place that are rigorous, open, and transparent.
Technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.
Faecal microbiota transplant for recurrent Clostridium difficile infection (HTG338)
Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridium difficile infection. This involves introducing enteric bacteria from the faeces of healthy donors to restore a healthy balance of bacteria in the gut.
People can comment on our guidance at specific stages in its development.
NICE public committee meetings supports our commitment to having processes in place that are rigorous, open, and transparent.
People can comment on our guidance at specific stages in its development.
We use 3 processes for assessing technologies: the single technology appraisal, the multiple technology appraisal and the cost comparison appraisal
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]
In development Reference number: GID-TA10489 Expected publication date: TBC
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]
Discontinued Reference number: GID-TA10070
Odevixibat for treating progressive familial intrahepatic cholestasis (HST17)
Evidence-based recommendations on odevixibat (Bylvay) for treating progressive familial intrahepatic cholestasis in people 6 months and older.
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]
Discontinued Reference number: GID-TA10334
Health Technology Assessment Innovation Laboratory (HTA Lab)
NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.
Otovent nasal balloon for otitis media with effusion (MIB59)
NICE has developed a medtech innovation briefing (MIB) on the Otovent nasal balloon for otitis media with effusion
Discontinued Reference number: GID-TA10202
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)
Discontinued Reference number: GID-TA10180
Any explanatory notes(if applicable) short‑term and long‑term: patient‑reported outcomes improvements in respiratory function adverse...
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
In development Reference number: GID-TA10886 Expected publication date: TBC
Evidence-based recommendations on cyanoacrylate glue occlusion for varicose veins. This involves injecting medical glue (cyanoacrylate) into a vein to close it with the aim of improving symptoms.
View recommendations for HTG540Show all sections
Endovenous mechanochemical ablation for varicose veins (HTG414)
Evidence-based recommendations on endovenous mechanochemical ablation for varicose veins. This involves using a rotating wire and chemical to close the varicose vein.
NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.
Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
More than 7,000 people in England will now be able to access to a life-extending treatment for advanced bowel cancer.